ELI LILLY AND COMPANY ✓ | ✓ |
✓ | ✓ |
✓
✓
✓
✓
Continuous Dosing
FDA Approval as
Monotherapy
Statistically Significant | PALOMA-3 | MONALEESA-3 & 7 | |
Overall Survival Benefit in | |||
Metastatic Breast Cancer | |||
Additional AI trial ongoing in 1L post-menopausal setting | Additional AI trial ongoing in 1L post-menopausal setting | Additional AI trial ongoing in 1L post-menopausal setting | |
Positive Trial in | PALLAS | ? NATALEE | |
Adjuvant Setting | |||
(PENELOPE-B adjuvant trial ongoing, late 2020 readout) | (2022 Interim, 2025 Primary readout) | ||
o o
0.5 | 1 | 1.5 | 2 | |||
o o
o
o
o
o
o
o o o
o o o
<
- <
≥
<
≥
0.5 | 1 | 1.5 | 2 | |
o o o
<
>
The most rapid timeline in the development of an oncology
medicine with multiple indications
Less than 3 Years
First Human Dose to Approval
Systemic Treatment | Treatment | Cabozantinib/ | Cabozantinib/ | Systemic Treatment | Treatment |
Naïve | Experienced | Vandetanib Naïve | Vandetanib | Naïve | Experienced |
Experienced | |||||
RET Fusion-Positive NSCLC | RET-Mutant MTC | RET Fusion-Positive Thyroid Cancers | |||
o o
o
o
Attachments
- Original document
- Permalink
Disclaimer
Eli Lilly and Company published this content on 21 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2020 16:19:02 UTC
